Abbott Q3 2026: sales up 14.5%, adjusted EPS $1.42, guidance held
Abbott's third quarter is a solid operating story wrapped in an ugly GAAP print: sales rose 14.5% to $13.01 billion and adjusted EPS climbed 9.2% to $1.42, yet net income fell 44.1% to $920 million. The gap is $0.89 a share of specified items, mostly intangible amortization and litigation. Read the 7.0% comparable growth as the real signal and the GAAP drop as the cost of the Exact Sciences deal.
1 · Expected vs. Actual
Free preview belowGAAP diluted EPS fell 43.6% to $0.53 while adjusted EPS rose 9.2% to $1.42, a hair under the $1.4297 consensus figure. The $0.89 per-share gap is made up of $841 million of intangible amortization, about $670 million of legal settlements and $178 million of acquisition, restructuring and other costs. Operating earnings fell 34.0% to $1.36 billion as R&D rose 20.1% and SG&A rose 39.8%.
Sales of $13.01 billion rose 14.5% from $11.37 billion, and the Exact Sciences acquisition alone accounted for $851 million of the $1.64 billion increase. Strip out the acquisition timing, currency and a Structural Heart compensation payment, and comparable growth was 7.0%. Medical Devices led at 7.8% comparable, ahead of Established Pharmaceuticals at 8.4%, Diagnostics at 6.4% and Nutrition at 4.9%.
Log in to read 35 analyses a week for free
Create a free account to read 35 full earnings analyses each week — all five steps: expected vs. actual, guidance tracker, money flow, balance sheet and risks. Members get unlimited access.
Figures on this page come from the company's original SEC filings. The analysis is generated automatically and checked against validation rules, but may still contain errors or omissions. Not investment advice. · Generated 2026-11-05
Answers are based on the earnings release and the analysis above. Free accounts get 3 questions a week; members get 30 a day.